Brookstone Capital Management Invests $275,000 in Harrow, Inc. (NASDAQ:HROW)

Brookstone Capital Management bought a new position in shares of Harrow, Inc. (NASDAQ:HROW) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 8,188 shares of the company’s stock, valued at approximately $275,000.

Other large investors also recently modified their holdings of the company. Quest Partners LLC bought a new stake in shares of Harrow during the 3rd quarter worth $29,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Harrow by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after buying an additional 227 shares during the last quarter. Hills Bank & Trust Co bought a new stake in shares of Harrow during the 3rd quarter worth $107,000. Huntington National Bank bought a new stake in shares of Harrow during the 3rd quarter worth $164,000. Finally, Clarus Group Inc. bought a new stake in shares of Harrow during the 3rd quarter worth $225,000. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Price Performance

Harrow stock opened at $33.85 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The company has a market capitalization of $1.21 billion, a PE ratio of -36.01 and a beta of 0.72. Harrow, Inc. has a 12 month low of $9.13 and a 12 month high of $59.23. The stock has a 50-day moving average price of $38.15 and a two-hundred day moving average price of $38.82.

Analyst Ratings Changes

HROW has been the subject of several recent analyst reports. B. Riley dropped their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th. Craig Hallum upped their price objective on Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. Finally, Lake Street Capital upped their price objective on Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, October 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.